Intraepidermal nerve-fibre density as a biomarker of the course of neuropathy in patients with Type2 diabetes mellitus

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F16%3A00065567" target="_blank" >RIV/65269705:_____/16:00065567 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/16:00090718

Výsledek na webu

<a href="http://onlinelibrary.wiley.com/doi/10.1111/dme.12890/abstract" target="_blank" >http://onlinelibrary.wiley.com/doi/10.1111/dme.12890/abstract</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/dme.12890" target="_blank" >10.1111/dme.12890</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Intraepidermal nerve-fibre density as a biomarker of the course of neuropathy in patients with Type2 diabetes mellitus

Popis výsledku v původním jazyce

AimsThis paper aims to investigate whether intraepidermal nerve-fibre density (IENFD) may be used as a marker of the course of neuropathy in patients with Type2 diabetes mellitus. MethodsSkin biopsies from the distal leg were serially evaluated in a group of 30 patients with Type2 diabetes mellitus (median age 60years, 17 men) with a short duration of diabetes (<3years) and good glucose control, and in 23 age- and sex-matched controls. The time intervals between biopsies were >2years (median 33.8months). Eighteen patients with Type2 diabetes mellitus had symptoms or signs of distal symmetrical diabetic polyneuropathy, 12 had no neuropathy. ResultsAt first skin biopsy, IENFD was normal in all controls and in patients without neuropathy (mean 9.5 and 7.9fibres/mm, respectively) compared with abnormal IENFD in 77.8% in patients with polyneuropathy (mean 3.4fibres/mm). The annual rate of intraepidermal nerve-fibre (IENF) loss expressed as a percentage of the first IENFD value in patients with diabetic polyneuropathy was significantly higher [mean (se), 11.95 (3.82)%] compared with controls [1.92 (1.81)%, P<0.001] and similar to patients without polyneuropathy [12.16 (4.38)%]. The rate of IENF loss did not correlate with degree of glucose control. ConclusionsThe annual rate of IENF loss in patients with Type2 diabetes mellitus was several times higher than that of healthy participants, irrespective of the presence of signs or symptoms of diabetic polyneuropathy at initial evaluation. The change in IENFD is not linear and should be expressed as a proportion of initial IENFD to serve as a marker of the course of diabetic neuropathy. What's new? Intraepidermal nerve-fibre loss in patients with Type2 diabetes mellitus is not linear and should be expressed as a proportion of initial intraepidermal nerve-fibre density.

Název v anglickém jazyce

Intraepidermal nerve-fibre density as a biomarker of the course of neuropathy in patients with Type2 diabetes mellitus

Popis výsledku anglicky

AimsThis paper aims to investigate whether intraepidermal nerve-fibre density (IENFD) may be used as a marker of the course of neuropathy in patients with Type2 diabetes mellitus. MethodsSkin biopsies from the distal leg were serially evaluated in a group of 30 patients with Type2 diabetes mellitus (median age 60years, 17 men) with a short duration of diabetes (<3years) and good glucose control, and in 23 age- and sex-matched controls. The time intervals between biopsies were >2years (median 33.8months). Eighteen patients with Type2 diabetes mellitus had symptoms or signs of distal symmetrical diabetic polyneuropathy, 12 had no neuropathy. ResultsAt first skin biopsy, IENFD was normal in all controls and in patients without neuropathy (mean 9.5 and 7.9fibres/mm, respectively) compared with abnormal IENFD in 77.8% in patients with polyneuropathy (mean 3.4fibres/mm). The annual rate of intraepidermal nerve-fibre (IENF) loss expressed as a percentage of the first IENFD value in patients with diabetic polyneuropathy was significantly higher [mean (se), 11.95 (3.82)%] compared with controls [1.92 (1.81)%, P<0.001] and similar to patients without polyneuropathy [12.16 (4.38)%]. The rate of IENF loss did not correlate with degree of glucose control. ConclusionsThe annual rate of IENF loss in patients with Type2 diabetes mellitus was several times higher than that of healthy participants, irrespective of the presence of signs or symptoms of diabetic polyneuropathy at initial evaluation. The change in IENFD is not linear and should be expressed as a proportion of initial IENFD to serve as a marker of the course of diabetic neuropathy. What's new? Intraepidermal nerve-fibre loss in patients with Type2 diabetes mellitus is not linear and should be expressed as a proportion of initial intraepidermal nerve-fibre density.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FB - Endokrinologie, diabetologie, metabolismus, výživa

OECD FORD obor

—

Projekt

<a href="/cs/project/ED1.1.00%2F02.0068" target="_blank" >ED1.1.00/02.0068: CEITEC - central european institute of technology</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Diabetic medicine

ISSN

0742-3071

e-ISSN

—

Svazek periodika

33

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

5

Strana od-do

650-654

Kód UT WoS článku

000375119500011

EID výsledku v databázi Scopus

—